f**********g
发帖数: 2252 | | s*****e
发帖数: 1368 | | l***y
发帖数: 582 | | s*****e
发帖数: 1368 | | f**********g
发帖数: 2252 | 5 Saw it up yersterday, but did not buy. | s*****e
发帖数: 1368 | 6 I believe other rumors will be out soon, but MM will kill all calls firstly. | X*****s
发帖数: 2767 | | y*****l
发帖数: 5997 | 8 BUY on Rumor works.
【在 s*****e 的大作中提到】
: rumor is out, hehe
|
| b*****h
发帖数: 783 | 9 trade on rumor is not a good strategy. the sale of its key product ZEVALIN
was not good , and sale of FUSILEV
will drop as the supply of generic back.
【在 y*****l 的大作中提到】
: BUY on Rumor works.
| X*****s
发帖数: 2767 | 10 7块6的时候想过要买一些，但大势不好没买
【在 f**********g 的大作中提到】
: Saw it up yersterday, but did not buy.
| y*****l
发帖数: 5997 | 11 Spectrum Pharmaceuticals Announces ZEVALIN(R) and Belinostat Abstracts to Be
Presented at the American Society of Clinical Oncology Annual Meeting
4 hours 16 minutes ago - BIZ via Comtex
BusinessWireSpectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development operations
with a primary focus in oncology, today announced ZEVALIN(R) (ibritumomab
tiuxetan) and Belinostat abstracts will be presented at the 2011 Annual
Meeting of the American Society of Clinical Oncology (ASCO), to be held June
3-7, 2011 at the McCormick Place Convention Center in Chicago, Illinois.
Summary abstract are now available for viewing on the ASCO website (www.asco
.org).
Friday, June 3, 2011
----------------------------------------------------------------------------
---
Time: 2:00pm to 6:00pm
Session: Leukemia, Myelodysplasia, and Transplantation
Type: Poster Discussion Session
Location: McCormick Place E450b
Abstract #6521 A Phase 1 and Pharmacodynamic (PD) Study
of the Histone Deacetylase (HDAC) Inhibitor Belinostat (BEL
) Plus
Azacitidine (AZC) in Advanced Myeloid Malignancies
-----------------------------------------------------------
------
Authors: O. Odenike et al.
Saturday, June 4, 2011
----------------------------------------------------------------------------
Time: 8:00am to 12:00pm
Session: Lymphoma and Plasma Cell Disorders
Type: Poster Discussion Session
Location: McCormick Place E450b
Abstract #8019 Use of Myeloablative Y90-Ibritumomab
Tiuxetan in Patients with High-Risk CD20+ NHL Not Eligible
for
Standard ASCT: Five-Year Results
-----------------------------------------------------------
---
Authors: L. Devizzi, et al.
Monday, June 6, 2011
-----------------------------------------------------------------------------
Time: 1:00pm to 5:00pm
Session: Lymphoma & Plasma Cell Disorders
Type: General Poster Session
Location: McCormick Place Hall A
Abstract #8048 Discriminatory Power of the (111)Indium
Scan ((111)In)
in the Prediction of Altered Biodistribution of
Radio-Immunoconjugate in the (90)-yttrium
Ibritumomab Tiuxetan Therapeutic Regimen: Meta-Analysis of
Five
Clinical Trials and 9 Years of Post-Approval Safety Data
-----------------------------------------------------------
----
Authors: Kylstra, Jelle W. - Spectrum Pharmaceuticals, Inc.
Online Only
Abstract #e18553 Consolidation Therapy With
Yttrium-90-Ibritumomab Tiuxetan In Follicular Lymphoma
Following
Induction With Modern Chemoimmunotherapy Regimens: A
Single-Institution Experience
--------------------------------------------------------
--------
Authors: N.V. Koshy, et al.
Abstract #e18503 Y90 Ibritumomab Tiuxetan With Maintenance
Rituximab As Initial Therapy For High Tumor Burden
Follicular
Lymphoma: A Wisconsin Oncology Network Study
---------------------------------------------------------
----
Authors: K. Thorhildur, et al
Abstract #e17511 Management of Thymic Epithelial Tumors
(TETs) at the National Cancer Institute (NCI)
---------------------------------------------
Authors: A. Rajan, et al
About Belinostat
Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being
studied in multiple clinical trials as a single agent or in combination with
chemotherapeutic agents for the treatment of various hematological and
solid cancers. Its anticancer effect is thought to be mediated through
multiple mechanisms of action, including the inhibition of cell
proliferation, induction of apoptosis (programmed cell death), inhibition of
angiogenesis, induction of differentiation, and the resensitization of
cells that have become resistant to anticancer agents such as platinums,
taxanes and topoisomerase II inhibitors. Belinostat is the only HDAC
inhibitor in clinical development with multiple potential routes of
administration, including intravenous administration, continuous intravenous
infusion and oral administration.
Belinostat is currently in a registrational trial, the BELIEF Study, under a
Special Protocol Assessment (SPA), as a monotherapy for relapsed or
refractory Peripheral T-Cell Lymphoma (PTCL), an indication for which it has
been granted Orphan Drug and Fast Track designations by the U.S. Food and
Drug Administration. Belinostat is also under investigation in a randomized
Phase 2 trial, as a combination therapy with carboplatin and paclitaxel, for
cancer of unknown primary (CUP). The CUP study is being run and fully
funded by our partner Topotarget A/S. Additionally, the National Cancer
Institute is currently conducting several clinical trials of belinostat in a
variety of hematological and solid tumors, both as monotherapy as well as
combination therapy.
About ZEVALIN(R) and the ZEVALIN Therapeutic Regimen
ZEVALIN (ibritumomab tiuxetan), injection for intravenous use is indicated
for the treatment of patients with previously untreated follicular non-
Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to
first-line chemotherapy. ZEVALIN is also indicated for the treatment of
patients with relapsed or refractory, low-grade or follicular B-cell non-
Hodgkin's lymphoma.
ZEVALIN is a CD20-directed radiotherapeutic antibody. The ZEVALIN
therapeutic regimen consists of three components: rituximab, Indium-111 (In-
111) radiolabeled ZEVALIN for imaging, and Yttrium-90 (Y-90) radiolabeled
ZEVALIN for therapy. The ZEVALIN therapeutic regimen is a form of cancer
therapy called radioimmunotherapy. Radioimmunotherapy (RIT) is an innovative
form of cancer treatment with a mechanism of action that is different from
traditional chemotherapy. RIT builds on the combined effect of a targeted
biologic monoclonal antibody augmented with the therapeutic effects of a
beta-emitting radioisotope.
Important ZEVALIN(R) Safety Information
Deaths have occurred within 24 hours of rituximab infusion, an essential
component of the ZEVALIN therapeutic regimen. These fatalities were
associated with hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic
shock. Most (80%) fatalities occurred with the first rituximab infusion.
ZEVALIN administration results in severe and prolonged cytopenias in most
patients. Severe cutaneous and mucocutaneous reactions, some fatal, can
occur with the ZEVALIN therapeutic regimen.
Please see full Prescribing Information, including Boxed WARNINGS, for
ZEVALIN and rituximab. Full prescribing information can be found at www.
ZEVALIN.com.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biotechnology company with fully integrated
commercial and drug development operations with a primary focus in oncology.
The Company's strategy is comprised of acquiring, developing and
commercializing a broad and diverse pipeline of late-stage clinical and
commercial products. The Company markets two oncology drugs, FUSILEV and
ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage
development along with a diversified pipeline of novel drug candidates. The
Company has assembled an integrated in-house scientific team, including
clinical development, medical research, regulatory affairs, biostatistics
and data management, formulation development, and has established a
commercial infrastructure for the marketing of its drug products. The
Company also leverages the expertise of its worldwide partners to assist in
the execution of its strategy. For more information, please visit the
Company's website at www.sppirx.com.
Forward-looking statement -- This press release may contain forward-looking
statements regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could cause actual
results to differ materially. These statements are based on management's
current beliefs and expectations. These statements include but are not
limited to statements that relate to our business and its future, including
certain company milestones, Spectrum's ability to identify, acquire, develop
and commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, leveraging the expertise of partners and employees,
around the world to assist us in the execution of our strategy, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical fact.
Risks that could cause actual results to differ include the possibility that
our existing and new drug candidates, may not prove safe or effective, the
possibility that our existing and new drug candidates may not receive
approval from the FDA, and other regulatory agencies in a timely manner or
at all, the possibility that our existing and new drug candidates, if
approved, may not be more effective, safer or more cost efficient than
competing drugs, the possibility that our efforts to acquire or in-license
and develop additional drug candidates may fail, our lack of revenues, our
limited marketing experience, our dependence on third parties for clinical
trials, manufacturing, distribution and quality control and other risks that
are described in further detail in the Company's reports filed with the
Securities and Exchange Commission. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to update the
information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. (R), ZEVALIN(R), and FUSILEV(R) are
registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER
CARE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by
Spectrum Pharmaceuticals, Inc.
(C) 2011 Spectrum Pharmaceuticals, Inc. All Rights Reserved
SOURCE: Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc.
Paul Arndt
Senior Manager, Investor Relations
702-835-6300 |
|
